Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin - PubMed (original) (raw)
Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin
Pyung-Hwan Kim et al. Biomaterials. 2011 Mar.
Abstract
PEGylation of adenovirus (Ad) increases plasma retention and reduces immunogenicity, but decreases the accessibility of virus particles to target cells. We tested whether PEGylated Ad conjugated to Herceptin (Ad-PEG-HER) can be used to treat Her2/neu-positive cells in vitro and in vivo to demonstrate the therapeutic feasibility of this Ad formulation. Ad-PEG-HER transduced Her2/neu-overexpressing cancer cells through a specific interaction between Herceptin and Her2/neu. Ad-PEG-HER treatment resulted in higher plasma retention and lower neutralizing antibody and IL-6 production than naked Ad. This formulation was extended to generate a Her2/neu-targeted, PEGylated oncolytic Ad (DWP418-PEG-HER). DWP418-PEG-HER specifically killed Her2/neu-positive cells and performed better than non-targeted and naked Ad in vivo. DWP418-PEG-HER showed a 10(10)-fold increase in the liver to tumor biodistribution compared with naked Ad. Immunohistochemical staining confirmed accumulation of Ad E1A in tumors. These data suggest that targeted gene therapy with the PEGylated Ad conjugated with Herceptin might shed a light on its therapeutic application for metastatic cancer in the future.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
- Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
Jung Y, Park HJ, Kim PH, Lee J, Hyung W, Yang J, Ko H, Sohn JH, Kim JH, Huh YM, Yun CO, Haam S. Jung Y, et al. J Control Release. 2007 Nov 6;123(2):164-71. doi: 10.1016/j.jconrel.2007.08.002. Epub 2007 Aug 15. J Control Release. 2007. PMID: 17854941 - Therapeutic targeting of chitosan-PEG-folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy.
Kwon OJ, Kang E, Choi JW, Kim SW, Yun CO. Kwon OJ, et al. J Control Release. 2013 Aug 10;169(3):257-65. doi: 10.1016/j.jconrel.2013.03.030. Epub 2013 Apr 4. J Control Release. 2013. PMID: 23562633 - [Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene].
Guo MG, Jiang MH, Yang Q, Li YM, Cui ZF, Li LF, Wu MC, Qian QJ. Guo MG, et al. Zhonghua Yi Xue Za Zhi. 2004 Jul 17;84(14):1147-51. Zhonghua Yi Xue Za Zhi. 2004. PMID: 15387973 Chinese. - Development of PEGylated adenovirus vector with targeting ligand.
Eto Y, Yoshioka Y, Mukai Y, Okada N, Nakagawa S. Eto Y, et al. Int J Pharm. 2008 Apr 16;354(1-2):3-8. doi: 10.1016/j.ijpharm.2007.08.025. Epub 2007 Aug 24. Int J Pharm. 2008. PMID: 17904316 Review.
Cited by
- Calibration of agent based models for monophasic and biphasic tumour growth using approximate Bayesian computation.
Wang X, Jenner AL, Salomone R, Warne DJ, Drovandi C. Wang X, et al. J Math Biol. 2024 Feb 15;88(3):28. doi: 10.1007/s00285-024-02045-4. J Math Biol. 2024. PMID: 38358410 Free PMC article. - Being Bayesian in the 2020s: opportunities and challenges in the practice of modern applied Bayesian statistics.
Bon JJ, Bretherton A, Buchhorn K, Cramb S, Drovandi C, Hassan C, Jenner AL, Mayfield HJ, McGree JM, Mengersen K, Price A, Salomone R, Santos-Fernandez E, Vercelloni J, Wang X. Bon JJ, et al. Philos Trans A Math Phys Eng Sci. 2023 May 15;381(2247):20220156. doi: 10.1098/rsta.2022.0156. Epub 2023 Mar 27. Philos Trans A Math Phys Eng Sci. 2023. PMID: 36970822 Free PMC article. - Active Targeting of Versatile Nanocomplex Using the Novel Biomarker of Breast Cancer Stem Cells.
Koh EY, Kim KS, Park HB, Kim JS, Kim PH. Koh EY, et al. Int J Mol Sci. 2022 Dec 30;24(1):685. doi: 10.3390/ijms24010685. Int J Mol Sci. 2022. PMID: 36614128 Free PMC article. - Efficient inference and identifiability analysis for differential equation models with random parameters.
Browning AP, Drovandi C, Turner IW, Jenner AL, Simpson MJ. Browning AP, et al. PLoS Comput Biol. 2022 Nov 28;18(11):e1010734. doi: 10.1371/journal.pcbi.1010734. eCollection 2022 Nov. PLoS Comput Biol. 2022. PMID: 36441811 Free PMC article. - Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens.
Kraft JC, Pham MN, Shehata L, Brinkkemper M, Boyoglu-Barnum S, Sprouse KR, Walls AC, Cheng S, Murphy M, Pettie D, Ahlrichs M, Sydeman C, Johnson M, Blackstone A, Ellis D, Ravichandran R, Fiala B, Wrenn S, Miranda M, Sliepen K, Brouwer PJM, Antanasijevic A, Veesler D, Ward AB, Kanekiyo M, Pepper M, Sanders RW, King NP. Kraft JC, et al. Cell Rep Med. 2022 Oct 18;3(10):100780. doi: 10.1016/j.xcrm.2022.100780. Epub 2022 Sep 26. Cell Rep Med. 2022. PMID: 36206752 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous